Ceralasertib for Advanced Cancer

"That is accurate. According to clinicaltrials.gov, this trial was posted on December 1st 2020 and is currently seeking 61 patients from 14 different sites."

"Ceralasertib's safety was estimated to be a 2 because, while there is some data supporting its safety, none of it speaks to the medication's efficacy."

"Ceralasertib was first researched in 2014 at a dedicated facility. Since then, 5 clinical trials have completed with positive results. There are presently 25 active investigations being conducted worldwide - many of which are based out of Indianapolis, Indiana."

"According to the latest information available on clinicaltrials.gov, this trial is still recruiting patients. The listing was first created on December 1st, 2020 and updated as recently as November 7th, 2022."

"Currently, there are 14 sites enrolling patients for this clinical trial. The locations of these clinics include Indianapolis, Duarte and New Orleans as well other cities. If you are interested in participating, please choose the location nearest to you to reduce travel burden."

"Currently, there are 25 ongoing clinical trials for Ceralasertib in 20 countries and 93 cities. The first study was held in 2014 and sponsored by AstraZeneca. This initial trial had 330 participants and completed both Phase 1 & 2 of drug approval. In the 6 years since the original study, 5 more have been conducted."

"According to the study's requirements for eligibility, any person aged 18-130 years old may enroll."

"The primary objective of this clinical trial, as measured over a period of From Screening (Day -28 to -1) until disease progression or withdrawal of consent (upto approximately 3 years), is Cohort B: Composite response rate by RECIST version 1.1. Additionally, this study will also be measuring secondary outcomes including Cohort B: Proportion of participants with confirmed CTC count conversion from unfavourable to favourable which is defined as Conversion of CTC count is defined as a conversion from unfavourable at baseline (≥ 5/7.5 mL blood) to favourable post-baseline (< 5/"

"This study is looking for 61 individuals who currently suffer from advanced solid tumours. Eligible participants must be between 18-130 years old and meet the following additional requirements: have a histologically confirmed diagnosis of AST (excluding NSCLC) or mCRPC tumour, documented prostate cancer progression while on androgen deprivation or after bilateral orchiectomy, have a deleterious or suspected deleterious ATM mutation in their tumour or blood, normal organ and bone marrow function, no curative treatment options, availability of archival or fresh tumour specimens, previously received and progressed on at least one novel hormonal agent , histologically confirmed"